Supplementary table 2: Comprehensive list of fields which were extracted from eligible studies
(*asterisk denotes variables for which outcome measures were collected*)

Data items	Prevalences	Mechanistic data	Analytical statistics
Title of study	Headache	C-reactive protein	Results from statistical tests reported by a study
CEBM Levels of Evidence	Myalgia	D-dimer	
Date of date collection	Asthenia	Antibodies	
Funding source	Dizziness/ vertigo	Cytokines	
Country of origin	Tinnitus	Creatine kinase	
Ethics statement	Hearing impairment	Computed tomography	
Number of recruitment settings	Ataxia	Magnetic resonance imaging	
Study design (including retrospective/ prospective)	Paresis	Electroencephalography	
Number of infected participants	Obsessions	Cerebrospinal fluid analysis	
Number of control participants	Palsy	Post-mortem findings	
Description of control group	Paraesthesia/numbness		
Population age (mean/median, sd/range)	Speech/aphasia		
Population sex (number male)	Focal neurological deficit		
Method of COVID-19 diagnosis	Seizures		
Stage of COVID-19 pathway	Neuralgia		
Severity of COVID-19	Ophthalmoplegia		
COVID-19 outcome	Visual defect		

Follow-up period	Fatigue*		
Time-point in relation to infection	Impaired smell*		
Treatments for neuropsych manifestations	Impaired taste*		
Neuropsychiatric and other relevant comorbidities	Cognitive impairment*		
Methodological limitations as noted by the authors	Depression*		
temporal onset of neuropsych complication (in relation to COVID-19 disease)	Anxiety*		
Method of ascertaining prevalence	Post-traumatic stress disorder*		
Nature of sample	Impaired consciousness/delirium/ encephalopathy*		
	Stroke		
	Meningoencephalitis		
	Guillain-Barre syndrome		
	Central demyelinating disorders		
	Motor neuropathy		
	Migraine		
	Sleep disorder		
	Catatonia		
	Dementia		
	Mania		
	Functional neurological disorder		
	Psychosis		

	Post-intensive care unit neuropsychiatric abnormality		
	Myopathy		
	Movement disorder		